This Article  • References  • Full text PDF  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Citation map  • Citing articles on HighWire  • Contact me when this article is cited  Related Content  • Similar articles in this journal  Social Bookmarking   What's this?

Dennis J. Meisner, MD; Raymond J. Carlson, MD; Arlan J. Gottlieb, MD

Arch Intern Med. 1985;145(4):700-702.

Abstract
• Procainamide hydrochloride—induced thrombocytopenia has infrequently been reported in the past. We report six cases of thrombocytopenia following the administration of the sustained-release form of procainamide. Three of these cases had platelet counts of less than 15,000/µL. The mean time to onset of thrombocytopenia from drug administration was 40 days (range, nine to 71 days). The mean time until normalization of the platelet counts after the drug therapy was stopped was 7.8±3.1 days (range, four to nine days). Oral prednisone therapy had little apparent benefit. The thrombocytopenia was not part of a systemic lupus erythematosus syndrome. We believe that thrombocytopenia is an important side effect of sustained-release procainamide therapy.

(Arch Intern Med 1985;145:700-702)

Author Affiliations
From the Department of Medicine, Upstate Medical Center, Syracuse, NY.

Footnotes
Accepted for publication Aug 13, 1984.

Reprint requests to Department of Medicine, Upstate Medical Center, Syracuse, NY 13210 (Dr Meisner).

CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter     What's this?

THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES

Pure Red Cell Aplasia Associated With Administration of Sustained-Release Procainamide
Giannone et al.
Arch Intern Med 1987;147:1179-1180.
ABSTRACT